Patents Assigned to Miotox, LLC
-
Patent number: 12364740Abstract: The present specification discloses methods for treating a PTSD. The methods comprise extramuscularly administering a Botulinum toxin to an individual in one or more areas of a fronto-fascial layer located in a frontal head region, one or more areas of a temporoparietal-fascial layer located in a temporal head region, and one or more areas of an occipito-fascial layer located in an occipital head region. The methods further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points and/or one or more subcutaneous locations in the head and neck and/or one or more sites of an epicranial aponeurosis. The methods further comprise intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitis muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.Type: GrantFiled: February 20, 2025Date of Patent: July 22, 2025Assignee: Miotox, LLCInventor: William J. Binder
-
Publication number: 20250186564Abstract: The present specification discloses methods for treating a PTSD. The methods comprise extramuscularly administering a Botulinum toxin to an individual in one or more areas of a fronto-fascial layer located in a frontal head region, one or more areas of a temporoparietal-fascial layer located in a temporal head region, and one or more areas of an occipito-fascial layer located in an occipital head region. The methods further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points and/or one or more subcutaneous locations in the head and neck and/or one or more sites of an epicranial aponeurosis. The methods further comprise intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitis muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.Type: ApplicationFiled: February 20, 2025Publication date: June 12, 2025Applicant: Miotox, LLCInventor: William J. Binder
-
Publication number: 20250108097Abstract: The present specification discloses methods and uses for treating a migraine disorder. The disclosed method comprising extramuscularly administering a Botulinum toxin to an individual in one or more areas of a fronto-fascial layer located in a frontal head region of the individual, one or more areas of a temporoparietal-fascial layer located in a temporal head region of the individual, and one or more areas of an occipito-fascial layer located in an occipital head region of the individual. The disclosed methods and uses further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points and/or one or more subcutaneous locations in the head and neck as well as one or more sites of an epicranial aponeurosis. The disclosed methods and uses further comprise intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitis muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.Type: ApplicationFiled: December 12, 2024Publication date: April 3, 2025Applicant: Miotox, LLCInventor: William J. Binder
-
Patent number: 12178862Abstract: The present specification discloses methods and uses for treating a migraine disorder. The disclosed method comprising extramuscularly administering a Botulinum toxin to an individual in one of more areas of a fronto-fascial layer located in a frontal head region of the individual, one of more areas of a temporoparietal-fascial layer located in a temporal head region of the individual, and one or more areas of an occipito-fascial layer located in an occipital head region of the individual. The disclosed methods and uses further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points and/or one or more subcutaneous locations in the head and neck as well as one or more sites of an epicranial aponeurosis. The disclosed methods and uses further comprise intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitus muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.Type: GrantFiled: June 3, 2021Date of Patent: December 31, 2024Assignee: Miotox, LLCInventor: William J. Binder
-
Publication number: 20210379166Abstract: The present specification discloses methods and uses for treating a migraine disorder. The disclosed method comprising extramuscularly administering a Botulinum toxin to an individual in one of more areas of a fronto-fascial layer located in a frontal head region of the individual, one of more areas of a temporoparietal-fascial layer located in a temporal head region of the individual, and one or more areas of an occipito-fascial layer located in an occipital head region of the individual. The disclosed methods and uses further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points and/or one or more subcutaneous locations in the head and neck as well as one or more sites of an epicranial aponeurosis. The disclosed methods and uses further comprise intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitus muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.Type: ApplicationFiled: June 3, 2021Publication date: December 9, 2021Applicant: Miotox, LLCInventor: William J. Binder
-
Patent number: 10201497Abstract: The present invention provides a method for treating a patient for migraine headache, including symptoms associated with migraine head ache, such as migraine associated vertigo, which comprises administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin, e.g. Botulinum toxin in a pharmaceutically safe form.Type: GrantFiled: April 28, 2017Date of Patent: February 12, 2019Assignee: Miotox, LLCInventor: William J. Binder
-
Publication number: 20170232080Abstract: The present invention provides a method for treating a patient for migraine headache, including symptoms associated with migraine head ache, such as migraine associated vertigo, which comprises administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin, e.g. Botulinum toxin in a pharmaceutically safe form.Type: ApplicationFiled: April 28, 2017Publication date: August 17, 2017Applicant: Miotox, LLCInventor: William J. Binder
-
Publication number: 20150231068Abstract: The present invention provides a method for treating a patient for migraine headache, including symptoms associated with migraine headache, such as migraine associated vertigo, which comprises administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin, e.g. Botulinum toxin in a pharmaceutically safe form.Type: ApplicationFiled: May 10, 2013Publication date: August 20, 2015Applicant: Miotox, LLCInventor: William J. Binder